Sequencing of the various new advanced prostate cancer treatments remains a hot topic in our community. What treatment should come first and will the combination of various treatments be even more effective? These types of questions are constantly buzzing around us and they will continue to as long as we develop new treatments. The only [...]
Again, prostate cancer confusion continues to reign. A recent study reported at the ASTRO (American Society for Radiation Oncology) conference claims that the addition of androgen deprivation therapy (ADT) in men with clinically localized prostate cancer was not associated with increased cardiovascular mortality. According to Jason A. Efstathiou, MD, Ph.D.l, of the Massachusetts General Hospital [...]
Recent data presented at the 2011 Genitourinary Cancers Symposium supports the growing consensus that intermittent androgen suppression (IADT) is no less effective than continuous androgen suppression at treating men with prostate cancer that recurs after radiotherapy. Lead investigator, Laurence Klotz, MD, chief of urology, Sunnybrook Health Sciences Center, and professor of surgery at the University [...]
Another small confirmatory study of acupuncture to treat the side effects of hormone deprivation (ADT) was published in the International Journal of Radiation Oncology. The study found that acupuncture appears to provide long-lasting relief to hot flashes, heart palpitations, and anxiety due to side effects of hormone treatment for prostate cancer. […]
One of the unsettled debates in our advanced prostate cancer world surrounds the issue of continuous vs. intermittent hormone therapy (IHT). Traditionally, hormone therapy was continuous, or once you started you never stopped the treatment. As many of us know, hormone therapy is notorious for damaging the quality of life. Hot flashes, loss of libido, [...]
Posted on the Prostate Problems Mailing list about two months ago was a notice from Dr. Richard Lam about a clinical trial in which his office, Prostate Oncology Specialists, will participate. What I found particularly interesting in this trial is that it was evaluating a potential new drug, abiraterone acetate, which could be used after [...]
A recent announcement about the once daily oral drug abiraterone acetate (CB7630) indicated that some of the current trial results demonstrate some efficacy in men with hormone refractory prostate cancer. The positive results appeared at two different stages of the standard treatment process. Positive results were demonstrated both before and after the administration of chemotherapy. [...]
